4506 On Other Exchanges
Symbol
Exchange
4506 is not on other exchanges.

sumitomo dainippon pharma co (4506) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SUMITOMO DAINIPPON PHARMA CO (4506)

Related News

No related news articles were found.

sumitomo dainippon pharma co (4506) Related Businessweek News

No Related Businessweek News Found

sumitomo dainippon pharma co (4506) Details

Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients, food additives, veterinary medicines, diagnostics, and others in Japan, China, North America, and other regions. The company offers pharmaceutical products, such as therapeutic agents for hypertension, angina pectoris, arrhythmia, Parkinson’s disease, systemic fungal infections, and hepatocellular carcinoma; atypical antipsychotics; rapid-acting insulin secretagogues; vasodilators; and biguanide oral hypoglycemic drugs. It also provides products for therapeutic indications, such as Anderson-Fabry disease, gastroprokines, antiepileptic, sedative hypnotics, short-acting and long-acting beta-agonist, corticosteroid nasal spray, inhaled corticosteroid, carbapenem antibiotics, and serotonin-agonist antianxiety drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, seasonings, and sweeteners; and chemical product materials, such as cosmetic and coating materials, active pharmaceutical ingredients, and electronic chemicals. Further, it provides veterinary medicines for companion animals, including dogs and cats; and farm animals, such as cattle, swine, horses, and cultured fish. Additionally, the company develops point-of-care testing diagnostic products for infectious diseases and acute myocardial infarctions; in-vitro diagnostics for bone and calcium metabolism, and central nervous system disorders; research materials that facilitate research related to medical care; and BBI608 and BBI503 anticancer drug candidates. It has a joint development agreement with Healios K.K. to develop iPS cell-derived retinal pigment epithelial cells for the treatment of age-related macular degeneration and other eye diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Dainippon Pharma Co., Ltd. operates as a subsidiary of Sumitomo Chemical Co. Ltd.

6,697 Employees
Last Reported Date: 06/23/16
Founded in 1897

sumitomo dainippon pharma co (4506) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sumitomo dainippon pharma co (4506) Key Developments

Sumitomo Dainippon Pharma Mulls Acquisitions

Sumitomo Dainippon Pharma Co., Ltd. (TSE:4506) intends to make acquisitions. President and Chief Executive Officer Masayo Tada said that the company is ready to consider future mergers and acquisitions in the cancer and neuropsychiatric areas, mainly overseas.

Sysmex Corporation, Healios K.K. and Sumitomo Dainippon Pharma Co., Ltd. Begin Joint R&D Related to Pre-Transplant Immune Reaction Testing Method for Retinal Pigment Epithelial Cells (RPE Cells) Derived from Allogeneic iPS Cells

Sysmex Corporation, HEALIOS K.K. and Sumitomo Dainippon Pharma Co., Ltd. announced that the three companies have begun pursuing joint research and development toward the establishment of a pre-transplant immune reaction testing method for retinal pigment epithelial cells (RPE cells) derived from allogeneic induced pluripotent stem (iPS) cells. iPS cell transplantation therapy is divided into two methods: autologous transplantation, where cells produced from iPS cells derived from a patient's own body, and allogeneic transplantation, which uses cells produced from iPS cells derived from a donor who meets certain criteria (allogeneic iPS cells). Autologous transplantation already has a track record of use in therapy, but involves a number of issues. This method requires producing iPS cells from a patient's own cells and then inducing cellular differentiation suitable for transplantation therapy. Producing cells for transplant requires time and the production costs are substantial. The method of allogeneic transplantation, on the other hand, may have the potential to provide cells with assured quality for transplantation therapy timely, stably and inexpensively, because allogeneic iPS cells are stored and managed in cell banks, and cells for transplant are produced systematically in standardized processes. However, since allogenic transplantation, --the treatment method using cells derived from allogeneic iPS cells-- may induce post-transplant immunorejection, it is necessary to develop a new testing method to confirm prior to transplantation whether cells are suitable for transplant, including the possibility to cause immunorejection.

Sumitomo Dainippon Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year End for the Fiscal Year Ending March 31, 2017; Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2016; Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2016 and Year Ending March 31, 2017

Sumitomo Dainippon Pharma Co., Ltd. expect to pay dividend for the second quarter and year end dividend of JPY 9.00 per share for the fiscal year ending March 31, 2017. The company reported consolidated earnings results for the first quarter ended June 30, 2016. For the quarter, the company reported net sales of JPY 103,488 million, operating income of JPY 14,555 million, ordinary income of JPY 12,685 million and net income attributable to owners of the parent of JPY 8,366 million or JPY 21.06 per share as compared to net sales of JPY 98,128 million, operating income of JPY 4,442 million, ordinary income of JPY 4,726 million and net income attributable to owners of the parent of JPY 5,941 million or JPY 14.95 per share for the same period a year ago. Income before income taxes was JPY 12,685 million compared to JPY 10,576 million a year ago. EBITDA was JPY 17.4 billion compared to JPY 9.7 billion a year ago. Return on equity (ROE) was 1.9% compared to 1.3% a year ago. Net cash used in operating activities was JPY 9.2 billion compared to net cash provided by operating activities of JPY 5.4 billion a year ago. Capital expenditures were JPY 1.3 billion compared to JPY 1.0 billion a year ago. Net sales increased by JPY 5.4 billion from the same period last year. This was driven primarily by North America segment. The operating income increased primarily because the gross profit significantly increased as the cost as a percentage of sales decreased. The exchange impact on the operating income was minus JPY 200 million for the quarter. The company provided consolidated earnings guidance for the six months ending September 30, 2016 and year ending March 31, 2017. For the six months ending September 30, 2016, the company expects net sales of JPY 199,000 million, operating income of JPY 16,000 million, ordinary income of JPY 16,000 million and net income attributable to owners of the parent of JPY 8,000 million or JPY 20.14 per share. EBITDA expects to be JPY 26.0 billion. For the year ending March 31, 2017, the company expects net sales of JPY 410,000 million, operating income of JPY 40,000 million, ordinary income of JPY 40,000 million and net income attributable to owners of the parent of JPY 25,000 million or JPY 62.92 per share. Capital expenditures expects to be JPY 10.0 billion. EBITDA expects to be JPY 61.0 billion.

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4506 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4506.
View Industry Companies
 

Industry Analysis

4506

Industry Average

Valuation 4506 Industry Range
Price/Earnings 27.5x
Price/Sales 1.8x
Price/Book 1.8x
Price/Cash Flow 22.8x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SUMITOMO DAINIPPON PHARMA CO, please visit www.ds-pharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.